Prestige Consumer Healthcare Inc. to Release Fiscal 2022 Second Quarter Earnings Results
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2022 second quarter earnings on November 4, 2021, before market opening. A conference call to discuss the results is scheduled for the same morning at 8:30 a.m. ET, with dial-in options available for U.S. and international participants. An archived replay will be accessible on the company's Investor Relations page. Prestige Consumer Healthcare markets a diverse range of health products across North America and internationally.
- Scheduled earnings release for Q2 2022 may indicate stability and transparency.
- Diverse portfolio of consumer healthcare products supports revenue generation.
- None.
TARRYTOWN, N.Y., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2022 second quarter earnings release on Thursday, November 4, 2021 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 7261575. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.
Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 7261575.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
FAQ
When will Prestige Consumer Healthcare release its Q2 2022 earnings?
What time is the earnings call for Prestige Consumer Healthcare?
How can I access the earnings call for PBH?
Where can I find the archived earnings call for PBH?
